HC Wainwright Expects Lower Earnings for Janux Therapeutics

Janux Therapeutics, Inc. (NASDAQ:JANX) – Stock analysts at HC Wainwright dropped their Q1 2025 earnings per share estimates for shares of Janux Therapeutics in a research report issued on Monday, March 3rd. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($0.48) for the quarter, down from their prior forecast of ($0.46). HC Wainwright currently has a “Buy” rating and a $70.00 price objective on the stock. The consensus estimate for Janux Therapeutics’ current full-year earnings is ($1.38) per share. HC Wainwright also issued estimates for Janux Therapeutics’ Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.46) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($1.86) EPS, FY2026 earnings at ($1.92) EPS, FY2027 earnings at ($1.77) EPS, FY2028 earnings at $0.28 EPS and FY2029 earnings at $2.82 EPS.

Janux Therapeutics (NASDAQ:JANX) last announced its earnings results on Thursday, February 27th. The company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%.

Other equities research analysts have also issued research reports about the company. Wedbush reissued an “outperform” rating and set a $76.00 target price (up previously from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. Cantor Fitzgerald reissued an “overweight” rating and set a $200.00 price target on shares of Janux Therapeutics in a research report on Wednesday, December 11th. Lifesci Capital raised Janux Therapeutics to a “strong-buy” rating in a research report on Friday, December 27th. BTIG Research boosted their price target on Janux Therapeutics from $82.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, December 3rd. Finally, Scotiabank lowered their price target on Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating for the company in a research report on Friday, February 28th. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $88.00.

Janux Therapeutics Price Performance

JANX stock opened at $31.50 on Thursday. The firm has a market capitalization of $1.65 billion, a P/E ratio of -26.92 and a beta of 3.16. The business’s 50-day moving average is $42.23 and its two-hundred day moving average is $47.67. Janux Therapeutics has a 1 year low of $29.63 and a 1 year high of $71.71.

Hedge Funds Weigh In On Janux Therapeutics

A number of hedge funds have recently modified their holdings of the stock. RA Capital Management L.P. grew its holdings in shares of Janux Therapeutics by 13.1% in the 4th quarter. RA Capital Management L.P. now owns 10,365,652 shares of the company’s stock worth $554,977,000 after acquiring an additional 1,200,000 shares during the last quarter. FMR LLC grew its holdings in shares of Janux Therapeutics by 10.8% in the 4th quarter. FMR LLC now owns 8,669,941 shares of the company’s stock worth $464,189,000 after acquiring an additional 845,266 shares during the last quarter. Janus Henderson Group PLC grew its holdings in shares of Janux Therapeutics by 41.2% in the 4th quarter. Janus Henderson Group PLC now owns 3,562,402 shares of the company’s stock worth $190,617,000 after acquiring an additional 1,038,996 shares during the last quarter. Paradigm Biocapital Advisors LP grew its holdings in shares of Janux Therapeutics by 46.5% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 3,515,986 shares of the company’s stock worth $188,246,000 after acquiring an additional 1,115,412 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. grew its holdings in shares of Janux Therapeutics by 47.6% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,061,750 shares of the company’s stock worth $163,926,000 after acquiring an additional 986,750 shares during the last quarter. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Janux Therapeutics

In other Janux Therapeutics news, CEO David Alan Campbell sold 25,000 shares of the stock in a transaction on Tuesday, December 24th. The stock was sold at an average price of $56.19, for a total transaction of $1,404,750.00. Following the completion of the transaction, the chief executive officer now directly owns 217,054 shares of the company’s stock, valued at approximately $12,196,264.26. This trade represents a 10.33 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Andrew Hollman Meyer sold 13,334 shares of the stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $54.88, for a total value of $731,769.92. Following the transaction, the insider now directly owns 82,139 shares of the company’s stock, valued at approximately $4,507,788.32. The trade was a 13.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 50,002 shares of company stock worth $2,684,703. 29.40% of the stock is currently owned by company insiders.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.